Renal manifestations of hepatitis C infection

American Journal of Medicine

Volumn 106, Issue 3, 1999, Pages 347-354

  Daghestani, Lena ^a   Pomeroy, Claire ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN; VIRUS RNA;

BONE MARROW SUPPRESSION; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; FEVER; HEPATITIS C; HUMAN; KIDNEY FUNCTION; NEPHROTIC SYNDROME; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLOMERULONEPHRITIS, MEMBRANOUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; KIDNEY; PROGNOSIS; RIBAVIRIN;

EID: 0033106209     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00014-5     Document Type: Review

References (103)

1. Dana F., Becherer P., Bacon B. Hepatitis C virus what recent studies can tell us . Postgrad Med. 95:1994;121-130.
2. Gumber S.C., Chopra S. Hepatitis C a multifaceted disease . Review of extrahepatic manifestations. Ann Intern Med. 123:1995;615-620.
3. Dienstag JL, Isselbacher KJ. Acute viral hepatitis. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 1994(2):1459-1481.
4. Bader T.F. Viral Hepatitis. 1997;135-208 H & H Publishers, Seattle.
5. Sharara A.I., Hunt C.M., Hamilton J.D. Hepatitis C. Ann Intern Med. 125:1996;658-668.
6. Davis C.L., Gretch D.R., Carithers R.L. Hepatitis C virus in renal disease. Curr Op Nephrol Hypertension. 3:1994;164-173.
7. Johnson R.J., Willson R., Yamabe H., et al. Renal manifestations of hepatitis C virus infection. Kidney Int. 46:1994;1255-1263.
8. Stehman-Breen C., Alpers C.E., Couser W.G., et al. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol. 44:1995;141-147.
9. Wejstal R., Widell A., Mansson A.S., et al. Mother to infant transmission of hepatitis C virus. Ann Intern Med. 117:1992;887-890.
10. Yoshioka K., Aiyama T., Okumura A., et al. Humoral immune response to the hypervariable region of hepatitis C virus differs between genotypes 1b and 2a. J Infect Dis. 175:1997;505-510.
11. Kanai K., Kako M., Okamoto H. HCV genotypes in the chronic hepatitis C and response to interferon. Lancet. 339:1992;1543.
12. Nomura H., Kimura Y., Tada H., et al. Predictive factors of a response to interferon therapy in chronic hepatitis C. J Clin Gastroenterol. 23:1996;185-189.
13. Yoshioka K., Kakumu S., Wakita T., et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy relationship to genotypes of hepatitis C virus . Hepatology. 16:1992;293-299.
14. Casato M., Agnello V., Pucillo L., et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglogulinemia associated with hepatitis C virus infection. Blood. 90:1997;3865-3873.
15. Adinolfi L.E., Utili R., Zampino R., et al. Effects of long-term course of alpha-nterferon in patients with chronic hepatitis C associated mixed cryoglobulinemia. Eur J Gastroenterol Hepatol. 9:1997;1067-1072.
16. Bell H., Hellum K., Harthug S., et al. Genotype, viral load, and age as independent predictors of treatment outcome of interferon-alpha treatment in patients with chronic hepatitis C. Scand J Infect Dis. 29:1997;17-22.
17. Saiz J.C., Lopez-Labrador F.X., Ampurdanes S., et al. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J Infect Dis. 177:1998;839-847.
18. Spengler U., Lechmann M., Irrgang B., et al. Immune responses in hepatitis C virus infection. J Hepatol. 24:1996;20-25.
19. Chisari F.V. Cytotoxic T cells and viral hepatitis. J Clin Invest. 99:1997;1472-1477.
20. Ogata N., Alter H.J., Miller R.H., Purcell R.H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA. 88:1991;3392-3396.
21. D'Amico G., Colasanti G., Ferrario F., Sinico R.A. Renal involvement in essential mixed cryoglobulinemia. Kidney Int. 35:1989;1004-1014.
22. Schifferli J.A., French L.E., Tissot J.D. Hepatitis C virus infection, cryglobulinemia, and glomerulonephritis. Adv Nephrol. 24:1995;107-129.
23. Agnello V. Mixed cryoglobulinemia and hepatitis C virus. Hosp Practice 1995 Mar 15;30:29-36.
24. Gorevic P.D., Kassab H.J., Levo Y., et al. Mixed cryoglobulinemia clinical aspects and long term follow up of 40 patients . Am J Med. 69:1980;287-308.
25. Harle J., Disder P., Dussol B., et al. Membranoproliferative glomerulonephritis and hepatitis C infection. Lancet. 341:1993;904.
26. Rollino C., Roccatell D., Giachino O., et al. Hepatitis C virus infection and membranous glomerulonephritis. Nephron. 59:1991;319-320.
27. Horikoshi S., Okada T., Shirato I., et al. Diffuse proliferative glomerulonephritis with hepatitis C virus-like particles in paramesangial dense deposits in a patient with chronic hepatitis C virus hepatitis. Nephron. 64:1993;482-484.
28. Davda R., Peterson J., Weiner R., Croker B., Lau J. Membranous glomerulonephritis in association with hepatitis C virus infection. Am J Kidney Dis. 22:1993;452-455.
29. Doutrelepont J.M., Adler M., Willens M., Yap S.H. Hepatitis C infection and membranoproliferative glomerulonephritis. Lancet. 341:1993;317.
30. Yamabe H., Johnson R.J., Gretch D.R., et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol. 6:1995;220-223.
31. Johnson R.J., Gretch D.R., Yamabe H., et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 328:1993;465-470.
32. Garcia-Valdecasas J., Bernal C., Garcia F., et al. Epidemiology of hepatitis C virus infection in patients with renal disease. J Am Soc Nephrol. 5:1994;186-192.
33. Mitwalli A., Al-Mohaya S., Al Wakeel J., et al. Hepatitis C in chronic renal failure patients. Am J Nephrol. 12:1992;288-291.
34. Yonemura K., Hishida A., Yoneyama T. High prevalence of hepatitis C virus antibody in patients with chronic renal failure at the start of hemodialysis therapy. Nephron. 73:1996;484-485.
35. Yamaguchi K., Nishumura Y., Fukuoka N., et al. Hepatitis C virus antibodies in hemodialysis patients. Lancet. 335:1990;1409-1410.
36. Oguchi H., Miyasalra M., Tokunoga S., et al. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Neprol. 38:1992;36-43.
37. Chauveau P., Courouce A.M., Lemarec N., et al. Antibodies to hepatitis C virus by second generation test in hemodialysed patients. Kidney Int. 43:1993;5149-5152.
38. Nui M.T., Coleman P.J., Alter M.J. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. Am J Kidney Dis. 22:1993;568-573.
39. Hardy N.M., Sandroni S., Danielson S., Wilson W.J. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol. 38:1992;44-48.
40. Forns X., Fernandez-Llama P., Pons M., et al. Incidence and risk factors of hepatitis C virus infection in a hemodialysis unit. Neprol Dial Transplant. 12:1997;736-740.
41. Knudsen F., Wantzin P., Rasmussen K., et al. Hepatitis C in dialysis patients relationship to blood transfusions, dialysis, and liver disease . Kidney Int. 43:1993;1353-1356.
42. Dussol B., Chichepottiche C., Cantaloube J.F., et al. Detection of hepatitis C infection by polymerase chain reaction among hemodialysis patients. Am J Kidney Dis. 22:1993;547-580.
43. Yamabe H., Fukushi K., Oshawa H., et al. Hepatitis C virus (HCV) infection may be an important cause of membranoproliferative glomerulonephritis (MPGN) in Japan. J Am Soc Nephrol. 4:1993;291. (Abstr).
44. Pasquariello A., Ferri C., Moriconi L., et al. Cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus. Am J Nephrol. 13:1993;300-304.
45. Rostoker G., Deforges L., Ben Maadi A., et al. Low prevalence of hepatitis C virus antibodies among adult patients with primary glomerulonephritis in France. Nephron. 63:1993;367.
46. Rostoker G., Deforges L., Ben Maadi A., et al. Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France. Nephron. 69:1995;97.
47. McOmish F., Yap P., Dow B., et al. Geographical distribution of hepatitis C virus genotypes in blood donors an international collaborative survey . J Clin Microbiol. 32:1994;884-892.
48. Willson R.A. Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol. 92:1997;4-15.
49. D'Amico G., Fornasieri A. Cryoglobulinemic glomerulonephritis a membranoproliferative glomerulonephritis induced by hepatitis C virus . Am J Kidney Dis. 25:1995;361-369.
50. Gonzalo A., Barcena R., Mampaso F., et al. Membranoproliferative glomerulonephritis and hepatitis C virus infection. Nephron. 63:1993;475-476.
51. Kaupke C.J., Vaziri N.D. Renal complications of hepatitis C virus infection. West J Med. 164:1996;442-443.
52. Burstein D.M., Rodby R.A. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. J Am Soc Nephrol. 4:1993;1288-1293.
53. Stehman-Breen C., Willson R., Alpers C., et al. Hepatitis C virus associated membranous glomerulonephritis. Curr Op Nephrol Hypertens. 4:1995;287-294.
54. Okada K., Takishita Y., Shimomura H., et al. Detection of hepatitis C virus core protein in the glomeruli of patients with membranous glomerulonephritis. Clin Nephrol. 45:1996;71-76.
55. Coroneos E., Truong L., Olivero J. Fibrillary glomerulonephritis associated with hepatitis C viral infection. Am J Kidney Dis. 29:1997;132-135.
56. Komatsuda A., Imai H., Wakui H., et al. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Int J Med. 35:1996;529-533.
57. Glassock RJ, Brenner BM. Nephrotic syndrome. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 1994(2):1459-1481.
58. Gonzalo A., Fernandez M., Navarro J., Ortuno J. Searching for hepatitis C virus antibodies in chronic primary glomerular diseases. Nephron. 69:1995;96.
59. Misiani R., Bellavita P., Fenili D., et al. Hepatitis virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med. 117:1992;573-577.
60. Johnson R.J., Gretch D.R., Couser W.G., et al. Hepatitis C virus associated glomerulonephritis. Effect of alpha interferon therapy. Kidney Int. 46:1994;1700-1704.
61. Pucillo L., Agnello V. Membranoproliferative glomerulonephritis associated with hepatitis B and C viral infections from virus-like particles in the cryoprecipitate to viral localization in paramesangial deposits, problematic investigations prone to artifacts . Curr Opin Nephrol Hypertens. 3:1994;465-470.
62. Agnello V., Chung R., Kaplan L. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 327:1992;1490-1495.
63. Lunel F. Hepatitis C virus and autoimmunity fortuitous association or reality? Gastroenterology. 107:1994;1550-1555. [editorial].
64. Pawlotsky J., Mustapha B., Andre C., et al. Immunological disorders in C virus chronic active hepatitis a prospective case-control study . Hepatology. 19:1994;841-848.
65. D'Amico G. Is type II mixed cryoblobulinemia an essential part of hepatitis C virus associated glomerulonephritis? Nephrol Dial Transplant. 1995;1279-1281.
66. Misiani R., Vicari O., Bellavita P., et al. Hepatitis C virus in renal tissue of patients with glomerulonephritis. Nephron. 68:1994;400.
67. Dentico P., Volpe A., Buongiorno R., et al. HCV third generation test in hemodialysis patients. Ital J Gastroenterol. 27:1995;300-302.
68. Medina M., Hill M., Sullivan H.O., et al. Detection of anti-hepatitis C virus antibodies in patients undergoing dialysis by utilizing a hepatitis C virus 3.0 assay: correlation with hepatitis C virus RNA. J Lab Clin Med. 132:1998;73-75.
69. Morosetti M., Sciarra G., Meloni C., et al. Membranoproliferative glomerulonephritis and hepatitis C effects of interferon-alpha therapy on clinical outcome and histological pattern . Nephrol Dial Transplant. 11:1996;532-534.
70. Hoofnagle J.H., Di Bisceglie A.M. The treatment of chronic viral hepatitis. N Engl J Med. 336:1997;347-356.
71. Hoofnagle J.H., Mullen J.D., Jones D.B., et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon a preliminary report . N Engl J Med. 315:1986;1575-1578.
72. Koff R.S. Therapy in chronic hepatitis C say goodbye to the 6-month interferon regimen [editorial] . Am J Gastroenterol. 91:1996;2072-2074.
73. Misiani R., Bellavita P., Fenili D., et al. Interferon alpha-2a therapy in cryoglobulinemia associated with hepatitis virus. N Engl J Med. 330:1994;751-756.
74. Karino Y., Toyota J., Sugawara M., et al. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol. 92:1997;61-65.
75. Gilli P., Stabellini N., Storari A., et al. Effect of human leukocyte alpha interferon on cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Nephrol Dial Transplantation. 11:1996;526-528.
76. Izopet J., Rostaing L., Moussion L., et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Clin Infect Dis. 176:1997;1614-1617.
77. Koenig P., Vogel W., Umlauft F., et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int. 45:1994;1507-1509.
78. Raptopoulou-Gigi M., Spaia S., Garifallow A., et al. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant. 10:1995;1834-1837.
79. Pol S., Thiers V., Carnot F., et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int. 47:1995;1412-1418.
80. Yamabe H., Johnson R., Gretch D., et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis. 25:1995;67-69.
81. Selby P., Kohn J., Raymond J., et al. Nephrotic syndrome during treatment with interferon. Br Med J. 290:1985;1180.
82. Janessen H., Brouwer J., Van der Mast R.C., Schalm S. Suicide associated with alpha-interferon therapy for chronic viral hepatitis. J Hepatol. 21:1994;241-243.
83. Papo T., Marcellin P., Bernuau J., et al. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med. 116:1992;51-53.
84. Garcia-Buey L., Garcia-Monzon, Rodriguez S., et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology. 108:1995;1770-1777.
85. DeVecchi A., Montagnino G., Pozzi C., et al. Intravenous methylprednisolone pulse therapy in essential mixed cryoglobulinemia nephropathy. Clin Nephrol. 19:1983;221-227.
86. Liaw Y., Sheen I., Lin S., et al. Effects of prednisolone pretreatment in interferon alpha therapy for patients with chronic non-A, non-B hepatitis. Liver. 13:1993;46-50.
87. Margin S., Craxi A., Fabiano C., et al. Hepatitis C viremia in chronic liver disease relationship to interferon alpha or corticosteroid treatment . Hepatology. 19:1994;273-279.
88. Lai M.Y., Kao J.H., Yang P.M., et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology. 111:1996;1307-1312.
89. Reichard O., Norkrans G., Fryden A., et al. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet. 351:1998;83-87.
90. Chemello L., Cavaletto L., Bernardinello, et al. The effect of interferon alpha and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol. 23:1995;8-12.
91. Blanche P., Bouscary D. Ribavirin therapy for cryoglobulinemia and thrombocytopenia associated with hepatitis C virus infection. Clin Infect Dis. 25:1997;1472-1473.
92. DiBisceglie A.M., Conjeerasam H.S., Fried M., et al. Ribavirin as therapy for chronic hepatitis C. Ann Intern Med. 123:1995;897-903.
93. Gane E., Lo S., Riordan S., Portmann B., Lau J., Naoumov N., Willimas R. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology. 27:1998;1403-1407.
94. Lopes E., Lopes L.V., Silva A.E. Mixed cryoglobulinemia and membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Ann Intern Med. 125:1996;781-782.
95. Quigg R.J., Brathwaite M., Gardner D.F., et al. Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Am J Kidney Dis. 25:1995;798-800.
96. Treichel U., Wandel E., Gerken G., et al. HCV associated cryoglobulinemia presenting with vasculitis, hepatitis, and glomerulonephritis-a therapeutic dilemma. Nephrol Dial Transplant. 11:1996;1168-1171.
97. Gorevic P.D., Kassab H.J., Levo Y., et al. Mixed cryoglobulinemia clinical aspects and long-term follow-up of 40 patients . Am J Med. 69:1980;287-308.
98. Geltner D. Therapeutic approaches in mixed cryoglobulinemia. Springer Semin Immunopathol. 10:1988;103-113.
99. Sarac E., Bastacky S., Johnson J. Response to high-dose interferon-α after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis. 30:1997;113-115.
100. Gallay B., Alpers C., Davis C., Schultz M., Johnson R. Glomerulonephritis in renal allografts associated with hepatitis C infection a possible relationship with transplant glomerulopathy in two cases . Am J Kidney Dis. 26:1995;662-667.
101. Brunkhorst R., Klein V., Koch K. Recurrence of membranoproliferative glomerulonephritis after renal transplantation in a patient with chronic hepatitis C. Nephron. 72:1996;465-467.
102. Hino K., Sainokami S., Shimoda K., et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol. 42:1994;299-305.
103. Ferri C., Marzo E., Longombardo G., Lombardini F., et al. Interferon-alpha in mixed cryoglobulinemia patients randomized, crossover-controlled trial . Blood. 81:1993;1132-1136.